Will BMS and Gilead divide hepatitis C treatment market?
BMS and Gilead have drawn a picture to divide the domestic hepatitis C treatment market.
According to the industry, the Ministry of Health and Welfare decided to register Sovaldi(generic name: sofosbuvir) and Harvoni(generic name: ledipasvir+sofosbuvir), Gilead’s hepatitis C treatments, for the...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
